구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Interleukin-2 (IL-2) |
Overview Company | Intima Bioscience, Inc. |
Overview Modality | ANTIBODY |
Overview Target | Renal Carcinoma |
Overview Indication | Acute Lymphoblastic Leukemia; Chronic Myelogenous Leukemia |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | targeted therapeutic approach to treating OA by blocking the iNOS-TXNIP-NLRP3 signaling |
MoA Biomarker | PD-L1 therapy, reduced CD8 + T-cell infiltration, and attenuated MHC-I expression |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Safety and Effectiveness of Denileukin Diftitox-cxdl in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma: An All-Case Post-Marketing Study in Japan.. Denileukin diftitox (DD)-cxdl, a fusion protein comprising diphtheria toxin fragments and human interleukin-2, is a treatment for peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). Previo… |
Clinical Safety signal | Safety and Effectiveness of Denileukin Diftitox-cxdl in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma: An All-Case Post-Marketing Study in Japan.. Denileukin diftitox (DD)-cxdl, a fusion protein comprising diphtheria toxin fragments and human interleukin-2, is a treatment for peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). Previo… |
Clinical Selected reported efficacy | ORR 59% |
Clinical Reported ORR | 59% |
Clinical Result source | ClinicalTrials.gov NCT03729245 |
Clinical Program phase | PHASE_1 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT03729245 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Interleukin-2 (IL-2) |
Overview Company | Intima Bioscience, Inc. |
Overview Modality | ANTIBODY |
Overview Target | Renal Carcinoma |
Overview Indication | Acute Lymphoblastic Leukemia; Chronic Myelogenous Leukemia |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | targeted therapeutic approach to treating OA by blocking the iNOS-TXNIP-NLRP3 signaling |
MoA Biomarker | PD-L1 therapy, reduced CD8 + T-cell infiltration, and attenuated MHC-I expression |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Safety and Effectiveness of Denileukin Diftitox-cxdl in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma: An All-Case Post-Marketing Study in Japan.. Denileukin diftitox (DD)-cxdl, a fusion protein comprising diphtheria toxin fragments and human interleukin-2, is a treatment for peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). Previo… |
Clinical Safety signal | Safety and Effectiveness of Denileukin Diftitox-cxdl in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma: An All-Case Post-Marketing Study in Japan.. Denileukin diftitox (DD)-cxdl, a fusion protein comprising diphtheria toxin fragments and human interleukin-2, is a treatment for peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). Previo… |
Clinical Selected reported efficacy | ORR 59% |
Clinical Reported ORR | 59% |
Clinical Result source | ClinicalTrials.gov NCT03729245 |
Clinical Program phase | PHASE_1 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT03729245 |
추천 비교
추천 비교